Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ST316 |
Synonyms | |
Therapy Description |
ST316 is a peptide antagonist that disrupts the interaction between beta-catenin and its co-activator BCL9, resulting in decreased downstream signaling and potentially leading to enhanced T-cell activation and inhibition of tumor growth (Cancer Res (2023) 83 (8_Supplement): LB016). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ST316 | ST 316|ST-316 | ST316 is a peptide antagonist that disrupts the interaction between beta-catenin and its co-activator BCL9, resulting in decreased downstream signaling and potentially leading to enhanced T-cell activation and inhibition of tumor growth (Cancer Res (2023) 83 (8_Supplement): LB016). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05848739 | Phase I | ST316 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |